JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Langen, K.-J.
Right arrow Articles by Coenen, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Langen, K.-J.
Right arrow Articles by Coenen, H. H.
Journal of Nuclear Medicine Vol. 42 No. 5 752-754
© 2001 by Society of Nuclear Medicine


BRIEF COMMUNICATION

Uptake of Cis-4-[18F]Fluoro-L-Proline in Urologic Tumors

Karl-Josef Langen, Anne Rose Börner, Volker Müller-Mattheis, Kurt Hamacher, Hans Herzog, Rolf Ackermann and Heinz H. Coenen

Institutes of Medicine and Nuclear Chemistry, Research Center Jülich, Jülich; and Clinics of Nuclear Medicine and Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Tumor uptake of the amino acid cis-4-[18F]fluoro-L-proline (cis-FPro) was studied with PET in eight patients with urologic tumors. Methods: Three patients had primary renal cell carcinomas (RCCs), one had a local recurrence of RCC, one had squamous RCC, one had an adrenal hemangioma, one had inguinal metastases of penile squamous carcinoma, and one had suspected metastatic disease from prostate cancer. PET scans of the trunk were acquired at 1 and 3–5 h after intravenous injection of 400 MBq cis-FPro and compared with 18F-FDG PET scans and CT. Results: None of the tumors or metastases showed significant uptake of cis-FPro. FDG uptake was seen in one of the three primary RCCs, in the local recurrence of RCC, in the squamous RCC, and in the metastases of penile cancer. Conclusion: Cis-FPro appears not to be a promising PET tracer in oncology.

Key Words: cis-4-[18F]fluoro-L-proline • radiolabeled amino acids • renal tumors • PET




This article has been cited by other articles:


Home page
JNMHome page
K.-J. Langen, D. Salber, K. Hamacher, G. Stoffels, G. Reifenberger, D. Pauleit, H. H. Coenen, and K. Zilles
Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4-18F-Fluoro- D-Proline
J. Nucl. Med., September 1, 2007; 48(9): 1482 - 1491.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. Scher, M. Seitz, M. Reiser, E. Hungerhuber, K. Hahn, R. Tiling, P. Herzog, M. Reiser, P. Schneede, and S. Dresel
18F-FDG PET/CT for Staging of Penile Cancer
J. Nucl. Med., September 1, 2005; 46(9): 1460 - 1465.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.